What Ultraproct L Treats: Main Uses and Benefits

Ultraproct L is a topical preparation that is commonly used for symptomatic relief in the anorectal region, particularly during conditions characterized by periods of heightened symptoms. Its combination of active ingredients is considered relevant for easing symptoms related to inflammatory or irritative states that interfere with daily comfort. The medication is commonly used across conditions presenting with acute episodes, such as haemorrhoids (piles), superficial anal fissures, and proctitis.

The treatment specifically helps address symptom clusters that may become intense, including: pain and discomfort, itching (pruritus ani), and burning sensation. The treatment helps contribute to improved comfort during these periods. A supportive feature is that the treatment provides support that helps ease the overall symptom burden and is applied during phases of increased distress or discomfort. It is primarily used when supportive symptom management is appropriate and may assist with maintaining functional stability.

---

“Provides support that helps ease the overall symptom burden.”

---

Quick Fact: Relief for Symptoms related to physical discomfort and Itching

Regulatory References

1. Ultraproct - Medsafe Consumer Medicine Information

Who can and cannot use Ultraproct L?

The eligibility for using Ultraproct L is strictly defined by regulatory documents, focusing on patient population and pre-existing conditions.

Absolute Contraindications

Use is contraindicated in patients with a known hypersensitivity to Fluocortolone, Lidocaine, or any excipient. The medicine must not be applied in the presence of untreated infections in the area, including those of bacterial, fungal, tuberculous, or syphilitic origin, or certain virus diseases (e.g., vaccinia, chickenpox).

---

Age and Physiological Restrictions

• Pregnancy: The medicine is contraindicated during the first trimester of pregnancy. For later trimesters and during lactation, use is conditional and requires a careful benefit-risk review; prolonged use must be avoided.
• Pediatric: Long-term continuous therapy is avoided in infants. Use in children under 12 is not recommended without specific medical guidance.

Conditional Eligibility

Eligibility is limited by co-treatment with CYP3A inhibitors, which should generally be avoided due to increased systemic risk. If co-existing bacterial or fungal infections are present, additional specific anti-infective therapy is required for use to be considered.

The interaction profile for Ultraproct L is structured around the potential for systemic absorption of its active substances, Fluocortolone and Lidocaine, from the site of administration. The regulatory documentation notes a pharmacokinetic interaction involving the corticosteroid component, Fluocortolone.

Pharmacokinetic and Exposure Modification

Co-administration with strong Cytochrome P450 3A (CYP3A) inhibitors, such as medicinal products containing ritonavir or cobicistat, is documented to inhibit the metabolism of Fluocortolone. This inhibition may result in increased systemic exposure to the corticosteroid. Due to this risk, this combination should generally be avoided unless the benefit outweighs the potential for systemic effects, necessitating careful patient monitoring.

Pharmacodynamic and Toxic Risk

The profile also includes two primary pharmacodynamic interaction domains related to the local anesthetic, Lidocaine. Concomitant use with Class I antiarrhythmic drugs carries a risk of additive systemic toxic effects, particularly affecting cardiac function. Similarly, co-administration with other oxidizing agents is noted for increasing the risk of methemoglobinemia.

Population-Dependent Considerations

The official documentation further specifies population-dependent risks. Patients diagnosed with severe hepatic disease or renal impairment are identified as having a higher potential for developing toxic plasma concentrations of the Lidocaine component due to compromised metabolic and clearance pathways.

The pharmacological action of Ultraproct L results from combining two distinct mechanisms of action: the anti-inflammatory pathway modulation of Fluocortolone and the neuronal membrane stabilization of Cinchocaine.

Suppression of the Inflammatory Cascade

The corticosteroid component, Fluocortolone, acts by binding to intracellular glucocorticoid receptors, which effectively modulates gene expression. This interaction inhibits the synthesis and release of pro-inflammatory mediators, such as prostaglandins and leukotrienes. This targeted inhibition of early molecular steps within the inflammatory cascade alters signaling dynamics, resulting in a reduction in local vascular permeability and mediator-driven vasodilation.

Targeted Blockade of Sensory Nerve Conduction

The local anesthetic component, Cinchocaine, functions as a neuronal membrane stabilizer by acting on voltage-gated sodium channels within the membranes of peripheral sensory nerve cells. By reversibly blocking the influx of sodium ions, it prevents the propagation of nerve impulses. This localized suppression of electrical activity prevents the initiation and conduction of afferent sensory impulses in the targeted peripheral neurons.

Biphasic Mechanism for Sustained Regulation

The formulation contains two Fluocortolone esters with different hydrolysis kinetics. This supports an extended temporal pattern of local glucocorticoid receptor engagement, which influences the sustained modulation of overactive physiological responses.

Ultraproct L is administered through two official routes: topical/perianal for external application and rectal for internal use, corresponding to the two available preparations. The high-level usage pattern defines the application unit as a thin layer—quantified as a pea-sized amount of ointment—or one suppository per administration.

The standard schedule of use is typically once or twice daily for sustained management. For rapid relief during the acute initial phase, the frequency can be increased to up to three or four times daily on the first day, followed by a return to the lower daily frequency. It is generally recommended that the medicine is best applied after defaecation and that the treatment area must be cleaned thoroughly prior to administration.

For correct administration, the enclosed nozzle (applicator) is required when using the ointment internally. The total treatment course is strictly time-limited, generally directed to not exceed four weeks in duration. To prevent relapse, the application is typically continued for at least one week after symptoms have completely resolved, but at a reduced frequency (e.g., ointment once a day or suppository every other day). Prolonged, continuous use is specifically advised to be avoided in pregnant or lactating women, as well as in infants and children.

Research Evidence / Overview of Studies for Ultraproct L

Evidence for the Management of Acute Anorectal Symptoms

Research into this medicine was conducted primarily through studies focusing on episodes where symptoms become more noticeable, which is relevant in evidence describing how symptoms are measured for conditions like hemorrhoids, anal fissures, and proctitis. Research has included large observational cohorts and smaller, controlled randomized trials, which are designs used in exploring how symptoms change over time. Research examined patient-reported outcomes describing perceived discomfort, including the severity of pain, itching, and general physical discomfort, alongside physical findings like swelling and bleeding.

Study Designs and Outcomes Tracked

This part outlines the different types of clinical research available, including large observational cohorts and randomized trials, and details the specific patient-reported and clinician-assessed measures (e.g., pain, bleeding, swelling scores) used to evaluate the product. Large-scale non-interventional studies, which evaluate use in observational settings, report how symptoms evolved in the observed populations over the study period. Research has explored patterns related to the measurement of the time to onset of the local anesthetic component following initial application.

Durability of Symptom Tracking and Follow-up Periods

This section details the observation periods used in the principal clinical research, noting the typical short-term duration of follow-up and characterizing the scope of information available on long-term disease stability or symptom recurrence.

The research exploring short-term symptom changes was observed in studies with follow-up durations that were limited, primarily extending up to 14 days. This defined time interval was used to track acute symptom variability and the evolution of discomfort. However, because the follow-up durations were limited, long-term outcomes are not fully established. The studies provide context for what has been observed so far, but do not provide insight into outcomes beyond the short-term treatment period.

What Remains Uncertain in the Evidence Base

The evidence base contributes to understanding symptom patterns, but several research limitation frames exist. For example, a considerable portion of the available data is derived from non-interventional or observational study designs. While this research describes how symptoms evolved in the observed populations in real-world settings, it does not provide the same level of evidence certainty as large, blinded randomized controlled trials, and therefore the evidence quality varies across studies. Dedicated research exploring the use of the combination in pediatric patients or for pregnancy-related hemorrhoidal symptoms has not been broadly published.

Key Studies & References

1. Ultraproct - Medsafe Consumer Medicine Information (CMI)

Common questions about Ultraproct L (FAQ)

Q: How is Ultraproct L described in comparison to other general over-the-counter hemorrhoid preparations?

Official information indicates that Ultraproct L is a prescription-only medicine defined as a fixed-dose combination product. It provides a dual action by pairing an anti-inflammatory corticosteroid (Fluocortolone) with a local anesthetic (Cinchocaine). This combination approach is noted in regulatory documents as a key factor distinguishing it from topical therapies that use only a single active substance.

Q: What are the three main active ingredients found in Ultraproct L?

According to the official product information, Ultraproct L contains three active components: fluocortolone pivalate, fluocortolone hexanoate, and cinchocaine hydrochloride. The two forms of fluocortolone are related substances that work together to help modulate local inflammation.

Q: What are the typical signs of an allergic skin reaction to Ultraproct L?

Allergic skin reactions (hypersensitivity) are classified in official documents as a rare effect associated with this medication. Patient information states that if signs of an allergic reaction are noticed, the documentation advises immediately stopping the application and seeking advice from a health professional.

Q: Does the Ultraproct L ointment formula contain any excipients that could potentially cause skin reactions?

Regulatory-aligned patient information confirms that the ointment does contain various excipients (inactive ingredients), including hydrogenated castor oil and a specific scented oil. It is noted that a known hypersensitivity to any excipient in the product is listed as a reason to avoid its use.

Q: Is the amount of active ingredients the same in Ultraproct L ointment and the suppositories?

Official product documentation specifies that the actual amount of active ingredients, such as cinchocaine hydrochloride, is not the same between the ointment and the suppository formulations.

Q: Is it necessary to inform a healthcare provider about all current medications, including non-prescription ones, before using Ultraproct L?

Official product information describes that it is advisable to inform a doctor or pharmacist about all medicines being taken, including non-prescription ones. This is due to the potential for certain drug interactions, such as with strong inhibitors of the CYP3A enzyme, which may increase exposure to the corticosteroid component.

Q: What should be done if an Ultraproct L suppository has become soft due to warm temperatures?

Official patient instructions specify that suppositories are stored in a refrigerator and not frozen. If they become soft due to heat, the documentation indicates they can be placed in cold water, without removing the wrapper, to regain a firm consistency before use.

Q: What is the guidance if symptoms do not show improvement after the initial treatment period?

Patient information indicates that if the condition persists or symptoms do not improve quickly, seeking advice from a doctor or pharmacist is the appropriate next step described in the documentation.

Q: What happens if Ultraproct L is accidentally swallowed?

If accidental oral intake occurs, such as swallowing several suppositories or a significant amount of the ointment, official safety information indicates that systemic effects are primarily expected from the anesthetic component, cinchocaine hydrochloride. These effects, depending on the amount ingested, could potentially lead to severe cardiovascular issues.

How to Store and Dispose of Ultraproct L?

Regulatory documents specify distinct storage conditions based on the formulation:

• Ointment: Must be stored below 25°C. The tube cap must be replaced tightly after use, and the product must be used within 3 months of opening.
• Suppositories: Must be stored in a refrigerator at 2°C to 8°C. The suppositories must not be frozen.

Child Safety and Disposal

All Ultraproct L formulations must be kept out of the sight and reach of children.

Unused or expired product must not be thrown away via household waste or wastewater. Disposal must be carried out in accordance with local requirements; patients are instructed to ask a pharmacist for guidance.